Goodwin Biotechnology Forms Supply Pact
By

Goodwin Biotechnology, Inc., a contract biologics manufacturer, has partnered with Aspyrian Therapeutics to complete process development, scale‐up, and cGMP manufacturing of Aspyrian’s antibody drug conjugate (ADC). Aspyrian Therapeutics recently submitted and has received US Food and Drug Administration’s acceptance of an investigational new drug application for RM‐1929, a targeted therapy for treating head and neck cancer.

Aspyrian Therapeutics secured an exclusive license from the National Cancer Institute for the new ADC technology platform, Near‐Infrared Photoimmunotherapy, which permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor. Because the payload in this ADC is inert until it is both in the tumor and activated by a laser using visible light, it overcomes the dose‐limiting adverse effects that have hindered the development of conventional, toxin‐loaded ADC systems, according to information from Goodwin Biotechnology. 

Source: Goodwin Biotechnology

Leave a Reply

Your email address will not be published. Required fields are marked *